Viatris Boosts Revenue and Raises Guidance Amid Strategic Moves
Event summary
- Viatris reported $3.8 billion in total revenues for Q2 2026, up 5% year-over-year, with a U.S. GAAP net loss of $119 million.
- The company raised its full-year 2026 financial guidance midpoints for all metrics, including total revenues and adjusted EBITDA.
- Viatris sold global rights to Tyrvaya® for an upfront payment of $30 million and additional milestone payments.
- The FDA approved Gwyn Lo™, a new combined hormonal contraceptive patch, expected to launch later this year.
The big picture
Viatris's Q2 2026 results reflect continued operational execution and strategic portfolio management. The company is focusing on high-growth opportunities, as evidenced by the sale of non-core assets like Tyrvaya® and the approval of new products such as Gwyn Lo™. The raised guidance suggests confidence in maintaining this trajectory amid broader industry trends toward consolidation and regulatory scrutiny.
What we're watching
- Execution Risk
- The impact of product supply disruptions due to manufacturing facility issues on second-half revenues.
- Regulatory Approvals
- The timeline and outcome of the FDA review for MR-107A-02, a non-opioid pain treatment.
- Strategic Focus
- Whether Viatris can sustain momentum from its enterprise-wide strategic review and pipeline progress.
Related topics